Dermus

The flagship product SkinScanner-M v.1.0 (“SSM”) integrates simultaneous optical and high-frequency ultrasound imaging for real-time visualization of both the surface and depth of the skin. It has achieved MDR Class IIa certification in Europe and has been validated by independent studies for melanoma staging and basal cell carcinoma subtype differentiation. Clinical collaborations include Mayo Clinic to further develop advanced cancer imaging solutions.

The device enables evidence-based diagnosis and monitoring of various dermatological conditions at point-of-care settings.

No drug or therapeutic clinical results as it’s a diagnostic device company.

Completed clinical trial at Semmelweis Medical University; commercial sales ongoing since late 2022.

Participated in UCB’s Digital Care Transformation Startup Program focused on hidradenitis suppurativa diagnosis.

Expanding distribution globally with new partnerships across North America, Europe, Middle East.

Raising €5 million to support global sales expansion as of early/mid–2025.